RXRX Stock Summary and Trading Ideas (Recursion Pharmaceuticals - Class A | NASDAQ:RXRX)

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Recursion Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol RXRX.

As of December 17, 2025, RXRX stock price climbed to $4.68 with 60,508,392 million shares trading.

RXRX has a beta of 3.45, meaning it tends to be more sensitive to market movements. RXRX has a correlation of 0.40 to the broad based SPY ETF.

RXRX has a market cap of $2.44 billion. This is considered a Mid Cap stock.

Last quarter Recursion Pharmaceuticals - Class A reported $5 million in Revenue and -$.36 earnings per share. This fell short of revenue expectation by $-13 million and exceeded earnings estimates by $.02.

In the last 3 years, RXRX traded as high as $16.75 and as low as $3.79.

The top ETF exchange traded funds that RXRX belongs to (by Net Assets): ARKK, VTI, ARKG, XBI, VB.

RXRX has underperformed the market in the last year with a return of -34.3%, while the SPY ETF gained +12.3%. In the last 3 month period, RXRX fell short of the market, returning -0.6%, while SPY returned +2.1%. However, in the most recent 2 weeks RXRX has outperformed the stock market by returning +0.4%, while SPY returned -1.8%.

RXRX support price is $3.98 and resistance is $4.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RXRX shares will trade within this expected range on the day.